Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

44 Results

Guidelines and Advice

Radionuclide Therapy for Patients with Neuroendocrine Tumors (NETs) in Ontario: Expert Panel Report

Status: Current
ID: GL-C50-01

Jan 2011

Statistical Reports

Cancer in First Nations in Ontario: Risk Factors and Screening Report

Mar 2017

Guidelines and Advice

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Status: In-Review
ID: GL-3-A-2016-1

Mar 2017

Guidelines and Advice

Recommendations on screening for breast cancer in average-risk women aged 40–74 years

Nov 2011

Guidelines and Advice

Complex Malignant Hematology Models of Care: Recommendations for Changes in the Roles and Composition of the Multidisciplinary Team and the Setting of Care to Improve Access for Patients in Ontario – March 2017

Status: Current
ID: GL-C50-31

Mar 2017

Drug

amsacrine

Other Name(s): AMSA P D® (Erfa)

Quick Link(s): Drug Monograph

Sep 2011

Regimen

CISPETOP(3D)

Cancer Type:

Unknown Primary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2017

Cancer facts

Number of Colorectal Cancer Screening Tests Performed in Ontario Plateaued

Mar 2017

Pages